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Worldwide concern over Zika virus causing Guillain–Barre syndrome (GBS) soared after 
recent reports that Zika-related weakness was due to GBS. A global strategic response 
plan was initiated with recommendations for at-risk countries to prepare for GBS. This plan 
has major economic implications, as nations with limited resources struggle to implement 
costly immunotherapy. Since confirmation of causality is prerequisite to providing specific 
management recommendations, it is prudent to review data endorsing a GBS diagnosis. 
We searched PubMed for manuscripts reporting original clinical, laboratory, and electrodi-
agnostic data on Zika virus and GBS. Five papers met criteria; four case reports and one 
large case–control study (French Polynesia) that attributed 42 paralysis cases to a motor 
variant of GBS. Brighton criteria were reportedly used to diagnose GBS, but no differential 
diagnosis was presented, which violates criteria. GBS was characterized by early onset 
(median 6 days post-viral syndrome), rapid progression (median 6 days from onset to nadir), 
and atypical clinical features (52% lacked areflexia, 48% of facial palsies were unilateral). 
Electrodiagnostic evaluations fell short of guidelines endorsed by American Academy of 
Neurology. Typical anti-ganglioside antibodies in GBS motor variants were rarely present. 
We conclude that there is no causal relationship between Zika virus and GBS because 
data failed to confirm GBS and exclude other causes of paralysis. Focus should be redi-
rected at differential diagnosis, proper use of diagnostic criteria, and electrodiagnosis that 
follows recommended guidelines. We also call for a moratorium on recommendations for 
at-risk countries to prepare costly immunotherapies directed at GBS.
Keywords: Zika virus, Guillain–Barre syndrome, acute flaccid paralysis, neurotropic virus, electrodiagnostic 
studies, nerve conduction studies, electromyography
iNtrODUctiON
Zika virus is a neurotropic Flavivirus that can cause disease within the central nervous system (CNS). 
The neurotropism of Flaviviruses is well-documented, and cases of acute flaccid paralysis due to 
myelitis with or without brainstem involvement have been reported with Dengue (1), Japanese 
encephalitis (2), Central European encephalitis (3), West Nile virus (4–6), and most recently, Zika 
in French West Indies (7) and French Polynesia (8). Moreover, in some newborns with microcephaly, 
brain tissue is positive for Zika virus RNA by reverse transcription-polymerase chain reaction 
(RT-PCR) assays, confirming the strong neurotropism of this virus (9). In contrast, the peripheral 
nervous system is usually spared in Flavivirus infections. Notably, non-poliovirus myelitis caused 
by a neurotropic virus can mimic Guillain–Barre syndrome (GBS) (10, 11), and patients presenting 
with acute flaccid paralysis due to viral myelitis are frequently misdiagnosed with GBS or a motor 
variant of GBS, as occurred after West Nile virus gained entry into North America in 1999 (4). The 
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acute flaccid paralysis associated with West Nile virus was errone-
ously attributed to GBS until late 2002, when electrodiagnostic 
and pathologic findings confirmed a poliomyelitis syndrome 
rather than a peripheral nerve disorder to explain the vast major-
ity of acute flaccid paralysis cases (5, 6). Considering the known 
neurotropism of Zika virus and other Flaviviruses, the ease with 
which viral myelitis can be confused with variants of GBS, and the 
fact that no confirmed outbreak of GBS has ever occurred with 
Flaviviruses, there is an urgent need to clarify whether the neu-
romuscular manifestations of Zika virus arise primarily from the 
peripheral or CNS. This will avoid history repeating itself, since 
the acute flaccid paralysis associated with Zika virus infection, like 
West Nile virus, has recently been attributed to GBS. Reports of 
Zika virus causing GBS were quickly endorsed by editorial teams, 
public health organizations, and the world press (12–14), and 
Zika virus was hastily added to the list of pathogens that precipi-
tate GBS (14, 15). By April 21, 2016, less than 2 months after the 
first published study describing a GBS outbreak (12), the World 
Health Organization (16) concluded that “based on a growing 
body of research, there is scientific consensus that Zika virus is a 
cause of GBS.” A strategic response plan was initiated, and at-risk 
countries were advised to prepare for GBS. That same month, the 
WHO reported over 600 new cases of Zika virus-related GBS in 
Latin American and Caribbean countries where gold-standards 
for confirming acute Zika virus infection and GBS were largely 
unavailable. Thus, precedence was quickly established for new 
cases of Zika virus acute flaccid paralysis to become Zika virus 
GBS, based solely or primarily on clinical grounds (17). This 
acceptance has major global economic implications, as nations 
with limited resources struggle to implement costly immuno-
therapy directed at a growing number of unconfirmed GBS cases. 
Since a clear understanding of the pathogenesis of Zika acute 
flaccid paralysis is a prerequisite to providing specific therapeutic 
and management recommendations, it is imperative and timely 
to review the data endorsing a diagnosis of GBS.
MetHODOLOGY
To this end, we performed a PubMed search using terms “Zika 
virus” and “GBS.” We also accessed information from national 
and international public health websites, including the Centers 
for Disease Control and Prevention,1 European Center for Disease 
Prevention and Control,2 and the WHO.3 As of June 28, 2016, the 
search returned 90 hits, which were reviewed for full text articles 
that reported original clinical, laboratory, and electrodiagnostic 
data on Zika virus and GBS.
OBservAtiONs/DiscUssiON
Five papers met criteria for providing original data (Table  1); 
four were case reports that described a total of five cases of classic 
demyelinating GBS in French Polynesia (18), Puerto Rico (19), 




large case–control study of a Zika virus outbreak in French 
Polynesia that attributed 42 cases of acute flaccid paralysis to 
the acute motor axonal neuropathy variant of GBS (12). This 
was the first and only study providing original clinical and 
electrodiagnostic evidence for Zika virus infection causing GBS, 
despite earlier suspicion of an association with GBS during the 
2013–2014 outbreak in French Polynesia (8, 22). Co-authors of 
the case–control study also published a second paper that pro-
vided additional information on presumably the same 42 GBS 
cases (23). The implication of the case–control study was that 
at-risk countries needed to prepare to manage patients with the 
motor variant of GBS. A commentary accompanying this paper 
endorsed the diagnosis of GBS by concluding “Zika virus can be 
added to our list of viruses that can cause GBS,” but also stressed 
the need for a better understanding of the pathogenesis of this 
disease (15). The GBS outbreak in French Polynesia combined 
with new clusters of paralysis attributed to GBS in the Americas 
created a substantial spike in new cases of GBS that, in conjunction 
with microcephaly cases, prompted the WHO to declare a Public 
Health Emergency of International Concern in February 2016. 
Prior to the case–control study in French Polynesia, there were 
only two single case reports of the demyelinating form of GBS 
associated with Zika virus infection [(18, 19), Table 1]. These two 
preceding case reports, and the subsequent two case reports, had 
little impact on changing the global perspective on Zika virus and 
GBS. It is difficult to determine whether these case reports even 
reflected a genuine increase in GBS precipitated by Zika virus or 
the result of enhanced reporting. Hence, the large case–control 
study provided the only evidence supporting a GBS etiology 
for Zika-related acute flaccid paralysis. A recent update on Zika 
virus-associated neurological disorders, published 4  months 
after the WHO declared a Public Health Emergency, described 
the case–control study from French Polynesia (12) as “the only 
report with reliable information on the diagnostic criteria used to 
identify suspect GBS cases associated with Zika virus infection” 
(24). Accordingly, it is this study that warrants further scrutiny.
The authors of the case–control study reported that the 
diagnosis of GBS was based on the Brighton criteria (25), which 
requires the absence of identified alternative diagnoses for weak-
ness. However, no differential diagnosis for a motor variant of 
GBS was presented, and there was no indication that mimics 
of GBS were identified or considered. This is a major omission 
because the absence of alternative diagnoses for weakness is the 
only diagnostic criteria in the Brighton criteria that is required 
for all four levels of GBS diagnostic certainty, ranging from level 
one (highest level of diagnostic certainty) to level four (reported 
as possible GBS due to insufficient data for further classification). 
Moreover, in the current clinical situation, non-poliovirus myeli-
tis is one of the major differential diagnoses of motor variants of 
GBS (10, 11). The clinical features of the 42 GBS cases also merit 
comment. In this series, 48% (13/27) of patients with facial palsy 
had unilateral weakness on admission. It is unclear if asymmetri-
cal weakness was also present in limb muscles because weakness 
was not expressed using Medical Research Council (MRC) scores 
or other GBS disability scales, and symmetrical weakness was not 
defined. Since GBS typically presents with symmetrical weak-
ness, a patient series in which nearly half of facial palsy patients 


















Case report 1 French 
Polynesia
Demyelinating (+) IgM, IgG; (+) 












Case report 1 Puerto Rico Demyelinating (+) IgM; (−) RT-PCR 




















Tetraparesis or paraparesis; 
areflexia; paresthesia; facial 






Case report 2 Martinique Demyelinating (+) RT-PCR in urine Cyto-albumin 
dissociation
Both cases: tetraparesis; 
areflexia; numbness; 










Paraparesis; facial palsy 
(bilateral)
AMAN, acute motor axonal neuropathy; bilat, bilateral; EDX, electrodiagnosis; GBS, Guillain–Barre syndrome; PRNT, plaque reduction neutralization test; RT-PCR, reverse 
transcription-polymerase chain reaction; (+), positive; (−), negative; unilat, unilateral.
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presented with unilateral weakness should raise concerns about 
alternative etiologies. Surprisingly, the majority of GBS patients 
(52%, 22/42) did not have areflexia or decreased reflexes at the 
nadir of the weakness. Given that loss of deep tendon reflexes is 
a classic feature of GBS that is required for three of four levels of 
GBS diagnostic certainty (Brighton levels 1–3), this finding alone 
casts doubts about the accuracy of the diagnosis. In the 42 GBS 
cases, 88% had a viral syndrome that preceded onset of neurologi-
cal symptoms by a median of only 6 days. The disease was also 
characterized by rapid progression (median of 6 days from onset 
to nadir). However, as acknowledged by the authors (12), GBS 
typically occurs 2–8 weeks after an infection, and motor dysfunc-
tion progresses over up to a 4-week period. This is in agreement 
with the time lag between acute rash attributed to Zika virus 
and cases of demyelinating form of GBS in Brazil, which peaked 
5–9 weeks after the rash (26). The cumulative clinical features of 
GBS cases from French Polynesia, including asymmetric weak-
ness, preserved reflexes, early onset and rapid evolution of the 
paralysis, are not characteristic of GBS and warrant consideration 
of alternative etiologies. In fact, as a group, the clinical presenta-
tion is more compatible with non-poliovirus (Flavivirus) myelitis 
than the acute motor axonal neuropathy variant of GBS (6, 27). 
The fact that typical anti-ganglioside antibodies seen with acute 
motor axonal neuropathy variant of GBS were rarely present 
in cases from French Polynesia (12) also raises concerns about 
alternative pathogenesis of the paralysis.
The electrodiagnostic results demand even greater scrutiny, 
since these studies represent the most important laboratory test 
to confirm GBS variants and to differentiate between GBS and 
its mimics. Co-authors of the case–control study also published 
the first case report of GBS occurring immediately after a Zika 
virus infection (18), which overlapped the study period in the 
case–control study. However, the electrodiagnostic findings in 
the case report “confirmed a diffuse demyelinating disorder,” as 
seen in other case reports (Table 1), rather than the acute motor 
axonal neuropathy variant of GBS, as reported later (12). The 
needle electromyogram (EMG) in the first case report, performed 
only a few days after onset of neurological symptoms, reportedly 
showed “acute denervation, without axonal abnormalities” (18). 
However, this is an implausible finding because acute denerva-
tion implies axonal loss, does not occur in acute demyelinating 
disorders, and usually manifests after a latent period of 2–3 weeks 
following the onset of axonal degeneration (28, 29). The authors 
of the case–control study and the subsequent paper on the 42 GBS 
cases reported results of “sensitive” nerve action potentials, rather 
than “sensory” nerve action potentials. The lack of acceptable 
terminology raises doubts about the authors’ and the reviewers’ 
familiarity with basic principles of nerve conduction studies. 
EMG data were not reported in the case–control study, another 
noteworthy omission because the needle examination is needed 
to confirm degeneration of motor axons and to look for asymmet-
ric denervation, a hallmark of Flavivirus myelitis (6). The authors 
also reported that nerve conduction studies showed the “same 
pattern in all tested nerves.” However, the various conduction 
abnormalities in all forms of GBS reflect the time at which studies 
are performed relative to disease onset and the temporal changes 
that occur in response to varying degrees of axonal degeneration 
and demyelination (27–29). Not surprisingly, serial conduction 
studies typically show large variability among different patients 
and even from one nerve to another in the same patient (28). 
Thus, it is difficult to conceive of consecutive GBS cases showing 
identical conduction abnormalities. In the case–control study, all 
37 patients who underwent electrodiagnostic testing “during the 
first week of GBS onset” reportedly showed conduction abnor-
malities (12). However, in the acute motor axonal neuropathy 
variant of GBS, conduction studies are typically normal within 
the first week of symptoms but defined abnormalities evolve with 
serial studies that clarify the diagnosis (27, 28). In a series of 31 
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patients with the acute motor axonal neuropathy variant of GBS, 
distal compound muscle action potential (CMAP) amplitudes 
(i.e., amplitudes of motor nerve responses) performed within the 
first week of disease onset were normal in 69 and 60% of median 
and ulnar nerves, respectively, while distal motor latencies were 
normal in 72 and 100% of median and ulnar nerves (27). This 
is in stark contrast to the electrodiagnostic results presented in 
the case–control study, where all motor nerve responses showed 
marked reduction of the distal CMAP amplitude and prolonged 
distal latencies in the first week (12). The small number of motor 
nerve conduction studies performed (one motor nerve in lower 
limbs and two in upper limbs) precluded a search for asymmetric 
involvement and warrant an explanation how a motor variant of 
GBS was diagnosed in 18 out of 42 cases (43%) that presented 
with muscle weakness confined to lower limbs. Given that the 
electrodiagnostic evaluation is an extension of the neurological 
examination, it is insufficient to examine only one motor nerve in 
the paraparetic lower limbs and two motor nerves in the asympto-
matic upper limbs. Indeed, a Position Statement by the American 
Association of Neuromuscular and Electrodiagnostic Medicine 
(29), endorsed by the American Academy of Neurology and the 
American Academy of Physical Medicine & Rehabilitation, reads: 
“In order to characterize the nature of a polyneuropathy (axonal 
or demyelinating, diffuse or multifocal) and in order to exclude 
polyradiculopathy, plexopathy, neuronopathy, or multiple mon-
oneuropathies, it may be necessary to study four motor and four 
sensory nerves, consisting of two motor and two sensory nerve 
conduction studies in one leg, one motor and one sensory nerve 
conduction study in the opposite leg, and one motor and one 
sensory nerve conduction study in one arm. At least two limbs 
should be studied by a needle EMG examination.” The electro-
diagnostic evaluations performed in French Polynesia clearly 
fall short of these guidelines. The interpretation of the available 
nerve conduction studies also conveys a limited understanding of 
the principles and practice of electrodiagnosis in neuromuscular 
diseases.
Data from the case–control study have been used to project 
the threat of Zika virus GBS in at-risk countries and to prepare 
for the anticipated GBS epidemic. A recent Viewpoint paper 
anticipating the challenges of Zika virus and the projected 
incidence of GBS in the United States (population 320 million) 
concluded that “as many as 30,000 cases of Zika virus-associated 
GBS might be expected,” assuming the risk of GBS of 0.24 per 
1,000 Zika virus infections and a 66% attack rate in those at risk 
(30). If true, the costs of GBS immunotherapy in the United 
States alone could be 500 million to 1 billion dollars4. The authors 
recommended careful planning to ensure an adequate supply and 
distribution of intravenous immune globulin and to maximize 
plasmapheresis availability (30), the two evidence-based acute 
treatments for GBS. In contrast, recent concerns have arisen 
regarding the epidemiological data used in the case–control study 
to support a causal relationship between Zika virus infection and 
GBS. Correspondence directed at the epidemiology argued that 
the association between GBS and Zika virus infection probably 
4 http://www.howmuchisit.org/how-much-does-ivig-cost/ (accessed August 1, 2016).
resulted from confirmation bias (31), the unconscious attempt 
to justify a conclusion already drawn instead of impartially 
collecting and assessing evidence to come to a valid conclusion 
(32). An accompanying correspondence also concluded that the 
“measure of association between Zika virus and GBS might be 
spuriously overestimated, perhaps markedly” (33).
cONcLUsiON
On the basis of our review, we conclude that evidence for a causal 
relationship between Zika virus infection and GBS is insufficient 
because clinical, serological, and electrodiagnostic data failed 
to confirm an acute motor axonal neuropathy variant of GBS 
and exclude other possible causes of paralysis. The acute flaccid 
paralysis associated with Zika virus was attributed to a motor 
variant of GBS, without considering alternative explanations, 
and quickly endorsed by reviewers, editorial teams, and national 
and international public health organizations. It merits further 
discussion how a case–control study without a secure diagnosis 
survived the rigorous scientific review process to mobilize a 
worldwide effort to tackle an unproven threat. This is particularly 
pertinent because there are no other studies that provide valida-
tion that Zika virus is a cause of GBS. While there may still be 
an association between Zika virus and the demyelinating form 
of GBS, based on published case reports (Table  1), it remains 
unclear if these few case reports reflect a genuine increase in GBS 
precipitated by Zika virus, the result of enhanced reporting, or 
confirmation bias. The distinction between acute flaccid paralysis 
due to GBS versus other causes has global economic implications 
because each case misdiagnosed and treated as GBS may cost tens 
of thousands of additional dollars.
Heretofore, we suggest that intensified focus be redirected 
at differential diagnosis, proper use of diagnostic criteria, and 
electrodiagnostic evaluations that follow recommended guide-
lines. This will help to clarify the pathogenesis of Zika virus 
acute flaccid paralysis. In this effort, experts in neuromuscular 
disorders should play a more important role. Until pathogenesis 
is established, we propose that new cases of Zika-related weak-
ness be termed “Zika virus acute flaccid paralysis,” rather than 
attributed to variants of GBS. We also call for a moratorium on 
recommendations for at-risk countries to prepare costly immu-
notherapies directed at GBS.
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